ACCC to prosecute Pfizer
The ACCC has alleged that prior to the expiration of the atorvastatin molecule patent in May 2012, Pfizer offered pharmacists significant discounts and the payment of rebates previously accrued on Lipitor sales. It said the discounts were conditional on pharmacies acquiring a minimum volume of up to 12 months’ supply of Lipitor and Pfizer’s own generic version of atorvastatin.
At the time of the offer, other companies seeking to enter the market with generic versions were prevented from making competing offers.
“The ACCC alleges